ProCE Banner Activity

CE / CME

Individualizing ART Management Based on Treatment Safety and Tolerability

In this interactive video module, expert faculty discuss safety and tolerability considerations for ART regimen selection and strategies to individualize regimen selection to reduce AEs associated with ART in persons with HIV

Pharmacists : 1.25 contact {hours} ({0.125} CEUs)

Physicians : maximum of 1.25 AMA PRA Category 1 {Credits}

Registered Nurses: 1.25 Nursing contact {hours}

Released: April 24, 2020

Expiration: April 23, 2021

No longer available for credit.

Share

Faculty

Kristine Erlandson

Kristine Erlandson, MD

Associate Professor
Division of Infectious Diseases
Department of Medicine
University of Colorado, Anschutz Medical Campus
Aurora, Colorado

Rajesh Gandhi

Rajesh Gandhi, MD

Assistant Professor of Medicine
Massachusetts General Hospital and Harvard Medical School
Boston, Massachusetts

Provided by

Provided by the USF Health
ProCE Banner

Supporters

Supported by an educational grant from

Janssen Therapeutics Division of Janssen Products

Target Audience

This program is intended for physicians, registered nurses, clinical pharmacists, and other healthcare providers who care for patients with HIV infection.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Incorporate the latest data on HIV regimen safety and tolerability into patient discussions of first-line ART options
  • Apply appropriate ART modification strategies for patients experiencing adverse events or who are at risk of other conditions for which ART safety may be a concern
  • Apply appropriate ART and non-ART medication management strategies for patients with multimorbidity and/or polypharmacy to avoid contraindications and minimize adverse events
  • Learning objectives apply to all professions

Faculty Disclosure

Primary Author

Kristine Erlandson, MD

Associate Professor
Division of Infectious Diseases
Department of Medicine
University of Colorado, Anschutz Medical Campus
Aurora, Colorado

Kristine M. Erlandson, MD, has disclosed that she has received funds for research support from Gilead Sciences and has served on advisory boards or panels with Gilead Sciences and ViiV Healthcare.

Rajesh Gandhi, MD

Assistant Professor of Medicine
Massachusetts General Hospital and Harvard Medical School
Boston, Massachusetts

Rajesh T. Gandhi, MD, has disclosed that he has no relevant conflicts of interest to report.

Staff Disclosure

Staff

Jennifer M. Blanchette, Ph.D.

Clinical Editor
Clinical Care Options, LLC

Jennifer M. Blanchette, PhD, has no relevant conflicts of interest to report.

Tiffany Hensley-McBain, PhD

Clinical Editor

Tiffany Hensley-McBain, PhD, has no relevant conflicts of interest to report.

Edward King, M.A.

Vice President, Editorial
Clinical Care Options, LLC

Edward King, MA, has no relevant conflicts of interest to report.

Carolyn Skowronski, PharmD

Associate Director, Scientific Services

Carolyn Skowronski, PharmD, has no relevant conflicts of interest to report.

Julie Skowronski, FNP-BC

Julie Skowronski, NP, has no relevant conflicts of interest to report.

Instructions for Credit

USF Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. 

Physician Continuing Medical Education

Credit Designation

USF Health designates this enduring material for a maximum of 1.25 AMA PRA Category 1 CreditsTM.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

USF Health is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

A maximum of 1.25 contact hours may be earned by learners who successfully complete this continuing nursing education activity.

USF Health is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This knowledge-based program has been approved for 1.25 contact hours (0.0125 CEU). Universal program number is as follows: 0230-9999-20-014-H02-P

Type of activity: Knowledge

For Pharmacists:
It is the responsibility of the pharmacy participant to ensure the provider has the learner’s birthday and e-Profile ID (ePID)/NABP number; it is the responsibility of the provider to submit to CPE Monitor participant information within 60 days of the activity for all participants who have attended, attested to their participation, and provided their ePID/NABP number and birthdate. 

ACPE indicates it is the responsibility of the pharmacy professional to confirm the status of their NABP contact hours before 60 days past the activity. If there are any discrepancies, contact the provider immediately. You may contact USF Health through cpdsupport@usf.edu.

Additional Information

Participation in this self-study activity should be completed in approximately 1.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from April 24, 2020, through April 23, 2021:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this activity is to improve learners’ competence in applying the latest safety and tolerability data when individualizing ART regimen selection and management for patients with HIV infection.